Dendritic cells crosspresent antigens from live B16 cells more efficiently than from apoptotic cells and protect from melanoma in a therapeutic model

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Matheoud, Diana ^a,b,c,d   Baey, Camille ^a,b,c   Vimeux, Lene ^a,b,c   Tempez, Andy ^a,b,c   Valente, Michael ^a,b,c   Louche, Pauline ^a,b,c   Le Bon, Agnès ^a,b,c   Hosmalin, Anne ^a,b,c   Feuillet, Vincent ^a,b,c  

^a INSTITUT COCHIN   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CYTOKINE; EPITOPE; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PURIFICATION; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE RELEASE; DENDRITIC CELL; LUNG METASTASIS; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; TUMOR CELL; TUMOR MODEL; ANIMAL; BIOSYNTHESIS; CELL SURVIVAL; CULTURE TECHNIQUE; DISEASE MODEL; EXPERIMENTAL MELANOMA; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY;

MUS;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CELL CULTURE TECHNIQUES; CELL SURVIVAL; CROSS-PRIMING; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-10; MELANOMA, EXPERIMENTAL; MICE;

EID: 79955725748     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019104     Document Type: Article

References (39)

1. Cresswell P, Ackerman AL, Giodini A, Peaper DR, Wearsch PA, (2005) Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol Rev 207: 145-157.
2. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S, (2002) Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20: 621-667.
3. Heath WR, Belz GT, Behrens GM, Smith CM, Forehan SP, et al. (2004) Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 199: 9-26.
4. Kono H, Rock KL, (2008) How dying cells alert the immune system to danger. Nat Rev Immunol 8: 279-289.
5. Kurts C, Robinson BW, Knolle PA, Cross-priming in health and disease. Nat Rev Immunol 10: 403-414.
6. Steinman RM, Banchereau J, (2007) Taking dendritic cells into medicine. Nature 449: 419-426.
7. Vulink A, Radford KJ, Melief C, Hart DN, (2008) Dendritic cells in cancer immunotherapy. Adv Cancer Res 99: 363-407.
8. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, et al. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2: 52-58.
9. Paglia P, Chiodoni C, Rodolfo M, Colombo MP, (1996) Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183: 317-322.
10. Speetjens FM, Kuppen PJ, Welters MJ, Essahsah F, Voet van den Brink AM, et al. (2009) Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res 15: 1086-1095.
11. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, et al. (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183: 87-97.
12. Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, et al. (2006) Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother 29: 545-557.
13. Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, et al. (2008) Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother 31: 101-112.
14. Salcedo M, Bercovici N, Taylor R, Vereecken P, Massicard S, et al. (2006) Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother 55: 819-829.
15. Berard F, Blanco P, Davoust J, Neidhart-Berard EM, Nouri-Shirazi M, et al. (2000) Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 192: 1535-1544.
16. Yu JS, Liu G, Ying H, Yong WH, Black KL, et al. (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64: 4973-4979.
17. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, et al. (2005) Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother 28: 496-504.
18. Chang AE, Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, et al. (2002) A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 8: 1021-1032.
19. Jenne L, Arrighi JF, Jonuleit H, Saurat JH, Hauser C, (2000) Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. Cancer Res 60: 4446-4452.
20. Toes RE, Ossendorp F, Offringa R, Melief CJ, (1999) CD4 T cells and their role in antitumor immune responses. J Exp Med 189: 753-756.
21. Schnurr M, Chen Q, Shin A, Chen W, Toy T, et al. (2005) Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 105: 2465-2472.
22. Gilboa E, Nair SK, Lyerly HK, (1998) Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 46: 82-87.
23. Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J, et al. (2003) Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J Immunol 171: 5940-5947.
24. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, et al. (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61.
25. Lotze MT, (2006) Cancer gene therapy: the power of negative thinking. Gene Ther 13: 191-193.
26. Green DR, Ferguson T, Zitvogel L, Kroemer G, (2009) Immunogenic and tolerogenic cell death. Nat Rev Immunol 9: 353-363.
27. Harshyne LA, Watkins SC, Gambotto A, Barratt-Boyes SM, (2001) Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J Immunol 166: 3717-3723.
28. Maranon C, Desoutter JF, Hoeffel G, Cohen W, Hanau D, et al. (2004) Dendritic cells cross-present HIV antigens from live as well as apoptotic infected CD4+ T lymphocytes. Proc Natl Acad Sci U S A 101: 6092-6097.
29. Matheoud D, Perie L, Hoeffel G, Vimeux L, Parent I, et al. (2010) Cross-presentation by dendritic cells from live cells induces protective immune responses in vivo. Blood 115: 4412-4420.
30. Joly E, Hudrisier D, (2003) What is trogocytosis and what is its purpose? Nat Immunol 4: 815.
31. Shen L, Rock KL, (2004) Cellular protein is the source of cross-priming antigen in vivo. Proc Natl Acad Sci U S A 101: 3035-3040.
32. Karttunen J, Sanderson S, Shastri N, (1992) Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc Natl Acad Sci U S A 89: 6020-6024.
33. Kurts C, Sutherland RM, Davey G, Li M, Lew AM, et al. (1999) CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc Natl Acad Sci U S A 96: 12703-12707.
34. Albert ML, (2004) Death-defying immunity: do apoptotic cells influence antigen processing and presentation? Nat Rev Immunol 4: 223-231.
35. Labarriere N, Bretaudeau L, Gervois N, Bodinier M, Bougras G, et al. (2002) Apoptotic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1 antigen. Int J Cancer 101: 280-286.
36. Rawson PM, Molette C, Videtta M, Altieri L, Franceschini D, et al. (2007) Cross-presentation of caspase-cleaved apoptotic self antigens in HIV infection. Nat Med 13: 1431-1439.
37. Uhl M, Kepp O, Jusforgues-Saklani H, Vicencio JM, Kroemer G, et al. (2009) Autophagy within the antigen donor cell facilitates efficient antigen cross-priming of virus-specific CD8+ T cells. Cell Death Differ 16: 991-1005.
38. Blachere NE, Darnell RB, Albert ML, (2005) Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation. PLoS Biol 3: e185.
39. Pang B, Neijssen J, Qiao X, Janssen L, Janssen H, et al. (2009) Direct antigen presentation and gap junction mediated cross-presentation during apoptosis. J Immunol 183: 1083-1090.